Case Reports in Urology
Volume 2019 (2019), Article ID 5734970, 1 page
https://doi.org/10.1155/2019/5734970

Corrigendum

Corrigendum to “Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy”

Abhishek Bhat,¹ Bruno Nahar,¹ Vivek Venkatramani,¹ Indraneel Banerjee,¹ Oleksandr N. Kryvenko,1,2,3 and Dipen J. Parekh1,3

¹Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA
²Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
³Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

Correspondence should be addressed to Abhishek Bhat; axb1722@med.miami.edu

Received 21 October 2019; Accepted 22 October 2019; Published 20 November 2019

Copyright © 2019 Abhishek Bhat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy” [1], the last sentence in the Abstract should be corrected from “We describe a case of a right-sided metastatic RCC with Level IV thrombus initially managed with Pazopanib followed by Nivolumab and Adalimumab followed by cytoreductive nephrectomy and IVC thrombectomy in the post-targeted therapy setting with complete curative response” to “We describe a case of a right-sided metastatic RCC with Level IV thrombus initially managed with neoadjuvant targeted therapy followed by cytoreductive nephrectomy and IVC thrombectomy in the post-targeted therapy setting with complete curative response”.

References

A. Bhat, B. Nahar, V. Venkatramani, I. Banerjee, O. N. Kryvenko, and D. J. Parekh, “Metastatic renal cell carcinoma with level IV thrombus: contemporary management with complete response to neoadjuvant targeted therapy,” Case Reports in Urology, vol. 2019, Article ID 7102504, 5 pages, 2019.